Over a year into the COVID-19 pandemic, clinicians’ worst fears about HIV and COVID-19 don’t appear to have materialized—but there remains a lot of uncertainty.
A new study shows that almost two-thirds of older adults who were diagnosed with HIV at a Connecticut clinic were already at an advanced stage of disease progression.
Two studies out of Europe aimed to give data on which patients with HIV benefit most from lipid-lowering medications, but they both ultimately concluded that better CVD risk-assessment tools—targeted specifically for PLWH—are needed.
Feb. 25, 2021: High HCV SVR among people using substances; geographic HIV care disparities among Black Americans; self-administered imiquimod vs. ASIL excision; PrEP uptake in syringe service programs.
“It’s About Our Community”: Newly Formed Science Initiative Aims to Center the Black Experience in HIV and COVID Care
Raniyah Copeland and Stephaun Wallace explain the mission and context for the Black AIDS Institute’s new Scientific Advisory Committee.
The findings add to evidence that injectable PrEP could ultimately have greater real-world efficacy than daily oral PrEP in many populations, thanks to better adherence.
Feb. 18, 2021: Insomnia rates among PLWH; trends in multimorbidity diagnosis; viral load control loss in the modern HIV treatment era; acceptability of HIV self-test dissemination methods.
Feb. 11, 2021: Early comorbidity development among women living with HIV; type 2 heart attack frequency; assessing European-based CVD assessment tools; long-term cognitive dysfunction and HIV/hepatitis coinfection.
New findings from the Antibody-Mediated Prevention (AMP) studies indicate that broadly neutralizing antibodies can work, but several will need to be used in combination.
Feb. 4, 2021: STI rates among PrEP users; how Medicaid expansion affects HIV testing and PrEP rates; utilizing mental health care providers in PrEP uptake; adapting HIV care in the COVID era.